HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
$480 million Business Combination to Accelerate the Commercialization of an Innovative FDA-Approved Cardiovascular Disease TreatmentNEW YORK & VERO BEACH, Fla.--(BUSINESS WIRE)--$ipo #Consumer--HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiov...
Source: pharmiweb.com